No Data
U.S. Food and Drug Administration Approves FoundationOneCDx and FoundationOneLiquid CDx as Companion Diagnostics for Lynparza (Olaparib) in Combination With Abiraterone for Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Express News | AstraZeneca Plans Presentations Across Its Portfolio And Pipeline At The IASLC 2024 World Conference On Lung Cancer And ESMO Congress
Berenberg Bank Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $99
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Reaffirms Their Buy Rating on AstraZeneca (AZN)
Several Reasons for the Outperformance of Astrazeneca Plc (AZN)
Green Dragon 2024 : That makes total sense. Especially, when Tom Lee stated that there should be a 40% growth in the small caps (Russell). Great information thank you!